DoD Awards $11M for Phase 2 Trial of TPIV110 Breast Cancer Therapy
News
The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy ... Read more